Compare DNUT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | FDMT |
|---|---|---|
| Founded | 1937 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.5M | 479.9M |
| IPO Year | 2021 | 2019 |
| Metric | DNUT | FDMT |
|---|---|---|
| Price | $3.67 | $10.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $4.15 | ★ $31.71 |
| AVG Volume (30 Days) | ★ 1.9M | 650.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,522,616,000.00 | $85,209,000.00 |
| Revenue This Year | $0.55 | N/A |
| Revenue Next Year | $3.59 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $2.58 | $3.03 |
| 52 Week High | $5.73 | $12.34 |
| Indicator | DNUT | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 60.76 |
| Support Level | $3.09 | $9.71 |
| Resistance Level | $3.87 | $10.70 |
| Average True Range (ATR) | 0.24 | 0.50 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 13.61 | 83.57 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).